University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Rajvir Dahiya, PhD

Rajvir Dahiya, PhD

Professor and Director, Urology Research Center, Department of Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

I have strong record of training post-doctoral fellows and visiting scientists. I have trained more than 50 postdoctoral fellows during my career, and most of my trainees currently hold faculty positions. I have published more than 300 research manuscripts in peer-reviewed journals. I have a broad background in molecular biology and genetics, with specific training and expertise in key research areas for this application. As a postdoctoral fellow at the University of Chicago, I gained expertise in the field of cancer biology. As PI or co-Investigator on previous NIH-funded grants, I laid the groundwork for the proposed research by developing various novel methods for epigenetic pathways, microRNAs, gene regulation, and function using both in vitro and in vivo models. In summary, I have a demonstrated record of successful and productive research projects in an area of cancer research that is a priority area since millions of people die of various malignancies every year.

Education

Kurukshetra University, India, MS, 1978, Biochemistry
Postgraduate Institute of Medical Education and Research, Chandigarh, India, PhD, 1982, Biochemistry
University of Chicago, Chicago, IL, Post-Doc, 1983-1987, Biochemistry


Professional Experience

  • 1987-1991
    Senior Scientist, Department of Medicine, University of California and VA Medical Center, San Francisco, CA
  • 1991-present
    Director of Urology Research, Department of Urology, University of California and VA Medical Center, San Francisco, CA
  • 1993-1997
    Associate Professor and Director Urology Research, Department of Urology, University of California and VA Medical Center, San Francisco, CA
  • 1997-present
    Professor, Department of Urology, University of California and VA Medical Center, San Francisco, CA
  • 2006-2011
    VA Research Career Scientist
  • 2011-2018
    VA Senior Research Career Scientist

Honors & Awards

  • 2006-2013
    Associate Editor, Cancer Research
  • 2013-present
    Associate Editor Clinical Cancer Research
  • 2011-present
    Academic Editor, PLoS ONE
  • 2011-present
    Senior Editor, Amer. J. Cancer Res.

Selected Publications

  1. Bucay N, Bhagirath D, Sekhon K, Yang T, Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto Y, Shiina M, Yamamura S, Tanaka Y, Deng G, Dahiya R, Saini S. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 2017 May 12.
    View on PubMed
  2. Hashimoto Y, Shiina M, Kato T, Yamamura S, Tanaka Y, Majid S, Saini S, Shahryari V, Kulkarni P, Dasgupta P, Mitsui Y, Sumida M, Deng G, Tabatabai L, Kumar D, Dahiya R. The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget. 2017 Mar 07; 8(10):16581-16593.
    View on PubMed
  3. Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R, Majid S. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 2017 Jan 26; 8(1):e2572.
    View on PubMed
  4. Shiina M, Hashimoto Y, Kato T, Yamamura S, Tanaka Y, Majid S, Saini S, Varahram S, Kulkarni P, Dasgupta P, Mitsui Y, Sumida M, Tabatabai L, Deng G, Kumar D, Dahiya R. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget. 2016 Dec 25.
    View on PubMed
  5. Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C, Mitsui Y, Deng G, Tabatabai ZL, Yamamura S, Calin GA, Dahiya R, Tanaka Y, Saini S. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene. 2016 Nov 28.
    View on PubMed
  6. Bucay N, Sekhon K, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Greene K, Tanaka Y, Dahiya R, Deng G, Saini S. Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. Oncotarget. 2016 Oct 25; 7(43):70388-70403.
    View on PubMed
  7. Sekhon K, Bucay N, Majid S, Dahiya R, Saini S. MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget. 2016 Oct 11; 7(41):67597-67611.
    View on PubMed
  8. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, Dasgupta P, Imai-Sumida M, Laura TZ, Greene K, Deng G, Dahiya R, Shahana M. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016 Sep 15.
    View on PubMed
  9. Shahryari V, Nip H, Saini S, Dar AA, Yamamura S, Mitsui Y, Colden M, Bucay N, Tabatabai LZ, Greene K, Deng G, Tanaka Y, Dahiya R, Majid S. Pre-clinical Orthotopic Murine Model of Human Prostate Cancer. J Vis Exp. 2016 Aug 29; (114).
    View on PubMed
  10. Mitsui Y, Chang I, Kato T, Hashimoto Y, Yamamura S, Fukuhara S, Wong DK, Shiina M, Imai-Sumida M, Majid S, Saini S, Shiina H, Nakajima K, Deng G, Dahiya R, Tanaka Y. Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer. Oncotarget. 2016 Aug 02; 7(31):49107-49121.
    View on PubMed
  11. Mitsui Y, Chang I, Fukuhara S, Hiraki M, Arichi N, Yasumoto H, Hirata H, Yamamura S, Shahryari V, Deng G, Wong DK, Majid S, Shiina H, Dahiya R, Tanaka Y. CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma. BMC Cancer. 2015; 15(1):942.
    View on PubMed
  12. Bucay N, Shahryari V, Majid S, Yamamura S, Mitsui Y, Tabatabai ZL, Greene K, Deng G, Dahiya R, Tanaka Y, Saini S. miRNA Expression Analyses in Prostate Cancer Clinical Tissues. J Vis Exp. 2015; (103).
    View on PubMed
  13. Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, Saini S, Deng G, Gill A, Wong DK, Shiina H, Nonomura N, Lau YF, Dahiya R, Tanaka Y. Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Oncotarget. 2015 Jun 30; 6(18):16341-51.
    View on PubMed
  14. Mitsui Y, Hirata H, Arichi N, Hiraki M, Yasumoto H, Chang I, Fukuhara S, Yamamura S, Shahryari V, Deng G, Saini S, Majid S, Dahiya R, Tanaka Y, Shiina H. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Oncotarget. 2015 Apr 20; 6(11):9577-91.
    View on PubMed
  15. Chang I, Mitsui Y, Fukuhara S, Gill A, Wong DK, Yamamura S, Shahryari V, Tabatabai ZL, Dahiya R, Shin DM, Tanaka Y. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget. 2015 Apr 10; 6(10):7774-87.
    View on PubMed
  16. Arichi N, Mitsui Y, Hiraki M, Nakamura S, Hiraoka T, Sumura M, Hirata H, Tanaka Y, Dahiya R, Yasumoto H, Shiina H. Versican is a potential therapeutic target in docetaxel-resistant prostate cancer. Oncoscience. 2015; 2(2):193-204.
    View on PubMed
  17. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 2015 Apr 1; 75(7):1322-31.
    View on PubMed
  18. Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, Saini S, Hirata H, Deng G, Gill A, Wong DK, Shiina H, Nonomura N, Dahiya R, Tanaka Y. DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget. 2014 Nov 30; 5(22):11297-307.
    View on PubMed
  19. Chang I, Fukuhara S, Wong DK, Gill A, Mitsui Y, Majid S, Saini S, Yamamura S, Chiyomaru T, Hirata H, Ueno K, Arora S, Shahryari V, Deng G, Tabatabai ZL, Greene KL, Shin DM, Enokida H, Shiina H, Nonomura N, Dahiya R, Tanaka Y. Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men. Tumour Biol. 2014 Oct; 35(10):10223-30.
    View on PubMed
  20. Saini S, Majid S, Shahryari V, Tabatabai ZL, Arora S, Yamamura S, Tanaka Y, Dahiya R, Deng G. Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther. 2014 Jul; 13(7):1952-63.
    View on PubMed

Go to UCSF Profiles, powered by CTSI